A study showed the Clostridioides difficile infection (CDI) treatment remained effective after subsequent systemic antibiotic exposure.
This article originally appeared on ContagionLive®.
The live biotherapeutic product (LBP) fecal microbiota, live-jslm (Rebyota), remained effective in preventing recurrence of Clostridioides difficile infection (CDI) in patients after subsequent systemic antibiotic exposure, according to a poster presented at IDWeek.
Specifically, a post hoc subgroup analysis from the PUNCH Open-Label phase 2 trial evaluated whether patients with multiple episodes of recurrent CDI (rCDI) who received 2 doses of Rebyota remained recurrence free when they were later exposed to antibiotic therapy for another condition, such as a urinary tract infection.
Among participants who received systemic antibiotics within 8 weeks, 6 months, 12 months, or 24 months of Rebyota administration, 91.6% (11 of 12), 95.7% (22 of 23), 90.6% (29 of 32) and 83.3% (30 of 36) remained free of CDI recurrence, respectively. Among all participants (N = 43), 86% were recurrence-free at their last evaluable time point.
“The real-world and clinical data presented at IDWeek reinforce the potential of Rebyota to prevent recurrent CDI and help patients suffering from this devastating disease,” Elizabeth Garner, MD, MPH, chief scientific officer, Ferring Pharmaceuticals US, said in a statement. “Initial experiences with Rebyota in physicians’ offices are promising and this is a positive step forward in changing the treatment paradigm for recurrent CDI.”
Antibiotics
Image credit: neirfy - stock.adobe.com
Investigators examined 43 participants, the mean age being 65.9 years with a majority being female (67.4%); nearly all of them (97.7%) had 3 or more rCDI episodes prior to LBP treatment.
“Most participants were treated with antibiotic monotherapy (n=34/43, 79.1%), received 1 course of treatment (n=28/43, 65.1%), and did not receive CDI prophylaxis (n=38/43, 88.4%),” the investigators wrote. “The median time to antibiotic exposure after the second dose of RBL [Rebyota] was 155 days (interquartile range [IQR], 55-349), and the median duration of treatment per antibiotic course was 8 days (IQR, 4.5-12.5).”
“RBL remained effective in preventing CDI recurrence in patients with multiple episodes of rCDI after subsequent systemic antibiotic exposure,” the investigators concluded.
Ferring's LBP Rebyota was FDA approved for rCDI last year.
Click here for more coverage of IDWeek 2023.
Reference
Reveles K, Gonzales-Luna A, et al. Efficacy of fecal microbiota, live-jslm after receipt of non–clostridioides difficile infection antibiotics: post hoc subgroup analysis of a phase 2 open-label trial. Presented at: IDWeek 2023. October 11-14, 2023; Boston, MA. Poster 702.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Bird Flu Risks, Myths, and Prevention Strategies: A Conversation With the NFID's Dr Robert Hopkins
January 21st 2025Joining us for this episode of Managed Care Cast is Robert H. Hopkins Jr, MD, medical director at the National Foundation for Infectious Diseases (NFID), who will help separate fact from fiction about avian influenza and discuss what needs to be done to prevent a future escalation.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More